An anti-depressant product made by Anglo-Swedish drugs titan AstraZeneca and US partner Targacept has failed to meet its initial target.
The product, known as as TC-5214, is intended to be used as an adjunct therapy to an anti-depressant in patients with major depressive disorder (MDD), who do not respond adequately to initial antidepressant treatment.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
In a statement the firm said: "TC-5214 was overall well tolerated in the study and showed an adverse event profile generally consistent with the earlier Phase IIb study. Analyses of the full data set from the study remain ongoing.
"TC-5214 has the potential to be a first-in-class nicotinic channel modulator to serve as an adjunct treatment for MDD in patients with an inadequate response to initial antidepressant therapies."
The results most recently announced are from the Renaissance 3 study, a flexible dose trial conducted in Europe.
NR
-
How to boost your pension pot as 35% of UK over 50s face huge retirement savings gapOver 50s are facing a later life with little to no funds - but there are steps you can take now to boost your pot.
-
Zoopla: House sales fall for first time in two years as buyers wait for Autumn BudgetThe average price of a house in September was £270,000, down £1,000 from August as the housing market’s Christmas slowdown came early, Zoopla says
